Innoviva, Inc. (INVA) Stock Forecast

NASDAQ: INVAAnalyst ratings, price target and estimates.

INVA analyst forecast

as of October 18, 2026
Analyst consensus
Buy
4.20 / 5 from 5 analysts
Price target
$35.00
average of analyst targets
Upside to target
+68.4%
from the latest close
Next earnings
November 4, 2026
EPS estimate $0.49
52-week range
$17.21 – $24.24

INVA analyst ratings

5 analysts
Strong buy
480%
Buy
00%
Hold
00%
Sell
00%
Strong sell
120%

Number of analysts at each rating.

INVA price target

Price $20.78Target $35.00
52-week low $17.2152-week high $24.24

The average of analyst 12-month price targets compared with the latest close and the 52-week range.

INVA earnings per share estimates

Innoviva, Inc. EPS estimates
PeriodAverageLowHighYear agoGrowthAnalysts
Current quarter (Sep '26)$0.34−$0.36$0.57$1.08−68.5%5
Current fiscal year (2026)$2.23$1.49$2.56$3.30−32.3%5
Next fiscal year (2027)$2.26$1.92$2.83$2.23+1.2%5

Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.

INVA revenue estimates

Innoviva, Inc. revenue estimates
PeriodAverageLowHighGrowthAnalysts
Current quarter (Sep '26)$115.3M$104.2M$132.9M+7.0%5
Current fiscal year (2026)$451.3M$421.5M$491.8M+9.7%5
Next fiscal year (2027)$490.0M$400.6M$578.0M+8.6%5

INVA EPS: reported and forecast

Reported EPSEstimate (average; low–high)

Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.

INVA revenue: reported and forecast

Reported revenueEstimate (average; low–high)

INVA EPS estimate revisions

Innoviva, Inc. EPS estimate revisions
Period90 days ago60 days ago30 days ago7 days agoNowChange (90 d)Revisions (30 d)
Current quarter (Sep '26)$0.38$0.38$0.25$0.25$0.34−10.5%1 up · 0 down
Current fiscal year (2026)$3.34$3.34$2.15$2.15$2.23−33.1%1 up · 0 down
Next fiscal year (2027)$2.29$2.29$2.33$2.33$2.26−1.1%0 up · 1 down

How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.

INVA earnings surprises

Reported EPSEstimate

Reported EPS vs the consensus estimate for the last 12 quarters; INVA beat in 7 of 12.

What analysts expect from INVA

5 analysts cover Innoviva; their consensus rating is buy (4.20 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.00, 68.4% above the latest close of $20.78. Analysts expect earnings of $2.23 per share for 2026, −32.3% from a year earlier. For 2027 the average estimate is $2.26 per share on revenue of $490.0 million. Innoviva beat the EPS estimate in 7 of the last 12 quarters.

Related: INVA income statement, INVA key metrics, INVA chart. See the INVA stock overview for the latest quote and news.

INVA forecast FAQ

What is Innoviva's price target?

The average analyst price target for Innoviva is $35.00, 68.4% above the latest close of $20.78.

Is Innoviva a buy, hold or sell?

Of 5 analysts covering Innoviva, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.

What is Innoviva's EPS forecast?

Analysts forecast $2.23 per share for 2026 (range $1.49 to $2.56); for 2027 the estimate is $2.26.

What is Innoviva's revenue forecast?

The average revenue estimate for 2026 is $451.3 million, growth of 9.7%; for 2027 it is $490.0 million.

When does Innoviva report earnings?

Innoviva is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.49.

Does Innoviva usually beat earnings estimates?

Innoviva reported EPS at or above the analyst estimate in 7 of the last 12 quarters.

Biotechnology: forecast